Top Biotech and Life Sciences Conferences to Attend in 2026 and 2027
Published 7/6/2026
Author: Andrew Reed, Assoc. Director, The Health Management Academy
Choosing Where to Spend Commercial Time
Deciding where commercial, medical, or business development teams should actually spend their limited time and budget is one of the most important decisions of any year. Budget, headcount, and prestige often dictate these decisions, yet access and format determine whether an event is actually worth the investment. A closed-door forum that seats fifty oncology commercial leaders across from the health systems that govern adoption produces different outcomes than a room full of thousands, but both have their place.
This guide is written for life sciences and biopharma leaders working in commercial, medical affairs, market access, business development, and investor-facing roles, as well as the health system executives they partner with. It covers the biotech and pharma conferences still ahead on the calendar, from the second half of 2026 into 2027. The goal is to assess the major industry events on their strengths, as well as any weaknesses. Every date and figure is drawn from each event's verified record. Where an edition is far enough out that the organizer has not published its agenda, pricing, or speakers, that is noted rather than estimated.
The Best Biotech and Life Sciences Conferences of 2026 and 2027
The Health Management Academy Industry Executive Convening
Dates and Location: Oncology Forum and Cardiovascular Forum, September 16–18, 2026, Boston, MA. Pharmacy Growth Collaborative, October 14–16, 2026, Boston, MA. Spring 2027 editions are expected but the dates are not yet published.
Who It Is For: Senior life sciences commercial, medical affairs, and market access executives, seated one-to-one with the health system service line leaders who govern oncology, cardiovascular, and pharmacy decisions.
Why It Stands Out: The Industry Executive Convening is the program on this list built specifically to connect life sciences teams with their customer, the health system executives who decide on pathways, formularies, and adoption. The forums run closed-door and retreat-style, with sessions shaped by the members themselves rather than a vendor-set agenda. The defining feature is a strict one-to-one health system-to-industry ratio to keep the dialogue balanced. The fall 2026 agenda concentrates on the questions defining the current landscape: AI adoption across care and commercialization, the integration of GLP-1 and cardiometabolic therapies, value-based transformation, pathway and formulary governance, 340B strategy and specialty drug access, ambulatory infusion, and the partnership models between manufacturers and health systems. THMA convenes a network that spans many of the country's largest systems, including Mayo Clinic, Cleveland Clinic, Kaiser Permanente, Providence, Mass General Brigham, Yale New Haven Health, Northwell Health, Intermountain Health, and Cedars-Sinai. The forums run without exhibit halls, vendor pitches, or media, and each room stays deliberately small, with each forum convening twenty-five to eighty executives in a retreat-style setting. These are application and membership-based gatherings rather than open-registration events, so they reward teams pursuing depth of relationship over breadth of exposure.
Best Suited For: Life sciences commercial and medical affairs teams whose central challenge is adoption and access, and who value sustained, peer-level relationships with health system decision-makers over a high volume of new contacts.
Fierce Pharma Week
Dates and Location: September 14–17, 2026 | Pennsylvania Convention Center, Philadelphia, PA
Who It Is For: Pharma commercial, marketing, medical affairs, and communications leaders.
Why It Stands Out: Fierce Pharma Week is the industry's cross-functional gathering for commercial strategy, organized across four communities that span pharma marketing, medical affairs, public relations, and commercialization. The program is built for the leaders who turn a product into a market strategy, with content on brand performance, market access, and patient engagement, and a speaker roster that has included executives from companies such as Bristol Myers Squibb. The commercial and communications focus is the boundary to plan around, since the program is built for go-to-market leadership rather than R&D, manufacturing, or investor audiences.
Best Suited For: Commercial and medical affairs leaders who want a concentrated read on where pharma marketing and market access are heading.
ISPE Annual Meeting and Expo
Dates and Location: October 18–21, 2026 | Gaylord National Resort and Convention Center, National Harbor, MD
Who It Is For: Pharmaceutical and biopharmaceutical professionals across engineering, manufacturing, supply chain, quality, and regulatory functions, from emerging talent to senior executives.
Why It Stands Out: The ISPE Annual Meeting and Expo is the leading gathering for the manufacturing and quality side of the industry, convening professionals from across pharmaceutical engineering and operations. The 2026 program is framed around modernization, sustainability, and harmonization, with technical sessions spanning facilities and production systems, supply chain resilience, quality systems, regulatory guidance, and AI and digital systems, alongside an extensive partner showcase. Registration is tiered across member, non-member, academia, government, recent graduate, and student categories, with membership required for all rates other than the non-member rate, and the meeting is offered both in person and virtually. The focus is the consideration here. This is an operations, engineering, and quality forum rather than a commercial or investor event, so its value concentrates among the teams responsible for making and supplying product.
Best Suited For: Manufacturing, quality, supply chain, and regulatory leaders focused on production systems and operational resilience.
HLTH USA
Dates and Location: November 15–18, 2026 | The Venetian Expo, Las Vegas, NV
Who It Is For: Life sciences and biopharma executives, digital health innovators, investors, payers, health systems, and startups.
Why It Stands Out: HLTH has become the leading cross-sector innovation event in U.S. healthcare, drawing more than 10,000 attendees and convening the commercial spectrum of the industry. For life sciences teams, the draw is a dedicated Pharma and Life Sciences Zone, a Market Connect one-to-one meeting program, a Startup Pitch Tournament, and an embedded Global Pharma Summit experience, with programming that spans AI drug discovery, GLP-1 disruption, clinical trials, commercialization, and patient access. Registration fees reflect the commercial orientation of guests, and qualifying participants and accredited media can attend through complimentary programs. The scale and vendor density are the tradeoff for teams that prefer closed-door dialogue, though the breadth of innovation exposure is difficult to match elsewhere.
Best Suited For: Commercial and digital innovation teams that need broad visibility into where patient engagement, partnerships, and new product launches are heading.
J.P. Morgan Healthcare Conference
Dates and Location: January 11–14, 2027 | The Westin St. Francis, San Francisco, CA
Who It Is For: Biopharma and biotech executives, institutional investors, venture capitalists, and senior healthcare leaders engaged in capital strategy.
Why It Stands Out: Each January, the J.P. Morgan Healthcare Conference makes San Francisco the center of healthcare investment for a week, drawing more than 8,000 executives, investors, and operators whose deals and conversations set the financial tone for the year ahead. The formal program runs strictly by invitation through J.P. Morgan, yet its influence spreads far beyond the host hotel: hundreds of satellite meetings, investor gatherings, and partnering sessions fill conference rooms across the city. Recent editions have centered on AI-driven drug discovery, obesity and GLP-1 therapeutics, large-scale M&A, and the emergence of women's health as a standalone investment vertical. The 2027 agenda has not yet been published. For health system leaders without an existing J.P. Morgan relationship, the invitation-only core remains the principal barrier to entry.
Best Suited For: Corporate development, investor relations, and executive leadership teams whose work touches capital allocation and strategic partnerships.
Biotech Showcase
Dates and Location: January 11–13, 2027 | Hilton San Francisco Union Square, San Francisco, CA
Who It Is For: Private and micro-to-mid-cap biotech companies, crossover and institutional investors, and business development teams seeking visibility during J.P. Morgan week.
Why It Stands Out: Biotech Showcase, co-produced by Demy-Colton and Informa Connect, is the most structured investor conference of J.P. Morgan week, purpose-built for the companies that are not on the main J.P. Morgan stage but still need serious investor exposure. Recent editions have drawn more than 3,200 global biopharma leaders, including over 1,200 investors and 350 or more presenting companies, with the partneringONE platform facilitating more than 6,000 one-to-one meetings. Specialized tracks such as TechBio Showcase and Seed Showcase give earlier-stage founders a platform alongside later-stage presenters. The 2027 registration rates have not yet been published. The event is built around investor partnering, so its return depends on arriving with a financing or business development agenda rather than a general interest in the field.
Best Suited For: Companies planning a financing round or business development conversations with crossover and institutional investors.
Advanced Therapies Week
Dates and Location: January 18–21, 2027 | San Diego Convention Center, San Diego, CA
Who It Is For: Cell and gene therapy developers, biomanufacturing and CDMO leaders, investors, regulators, CROs, academics, and patient advocates.
Why It Stands Out: Advanced Therapies Week, produced by Phacilitate, is one of the most established cell and gene therapy gatherings on the calendar, convening the advanced modality ecosystem from discovery through commercial scale-up. Recent editions have brought together more than 2,000 leaders with over 250 speakers, 3,000 or more one-to-one meetings, and 200-plus exhibitors, alongside a dedicated Investment Summit, across five content tracks spanning manufacturing, commercialization, regulation, and investment. For 2027, the event moves earlier into January, closer to the J.P. Morgan-anchored start of the year, and tiered passes are available through the official site. The concentration on cell and gene therapy is the defining boundary, which makes the event essential for teams working in advanced modalities and adjacent for those outside them.
Best Suited For: Teams developing, manufacturing, or commercializing cell and gene therapies and other advanced modalities.
BIO Investment and Growth Summit
Dates and Location: February 16–17 2027 | Eden Roc, Miami Beach, FL
Who It Is For: Biotech chief executives, venture and crossover investors, bankers, and heads of business development at biopharma companies.
Why It Stands Out: The BIO Investment and Growth Summit, known as the BIG Summit, is BIO's business development and investment event, convening more than 400 investors, biotech innovators, and biopharma executives in Miami Beach across two days. The program centers on the financial landscape for life sciences, dealmaking data, the outlook for the IPO window, and the regulatory and policy shifts that affect biotech, with BIO Partnering meetings for licensing and royalty discussions and company presentations that raise visibility with capital providers. It draws venture investors, crossover investors, and bankers alongside company leadership, which makes it a concentrated setting for financing and partnership conversations. The investor and business-development focus is the boundary here, since the program is built for capital formation rather than scientific or commercial programming,
Best Suited For: Biotech leadership and business development teams focused on financing strategy, partnering, and capital formation.
BIO International Convention
Dates and Location: June 7–10, 2027 | Pennsylvania Convention Center, Philadelphia, PA
Who It Is For: C-suite biotech and biopharma executives, scientists, investors, regulators, policymakers, patient advocates, and international delegations.
Why It Stands Out: The BIO International Convention is the largest and most comprehensive event in biotechnology, drawing roughly 20,000 industry leaders from around the world alongside more than 1,600 exhibitors and 135 or more sessions in recent editions. Its BIO Partnering platform hosts more one-to-one meetings than any other event in the industry, which is the central reason senior business development teams attend. Programming spans next-generation biotherapeutics, cell and gene therapy, rare disease, biomanufacturing, and regulatory and policy questions, along with the Start-Up Stadium pitch program for emerging founders. The convention relocates to Philadelphia for 2027, and registration opens in January 2027 with rates that scale by membership status and access level. The scale is the tradeoff, since the convention rewards teams that arrive with a defined partnering plan and weighs less toward unstructured attendance.
Best Suited For: Companies seeking pharmaceutical partners, institutional investors, international market entry, or CDMO relationships.
DIA Global Annual Meeting
Dates and Location: June 28–July 1, 2027 | San Diego Convention Center, San Diego, CA
Who It Is For: Industry, regulatory and government, academic, and patient representatives across drug development, regulatory affairs, clinical, and medical affairs functions.
Why It Stands Out: The DIA Global Annual Meeting is a flagship forum for the regulatory and drug development community, convening industry, regulators, academics, and patients to work through the challenges facing the life sciences ecosystem. Programming spans global and local regulatory questions, real-world data strategy, AI in regulatory science, and patient engagement, and the meeting runs in a hybrid in-person and virtual format. The regulatory and clinical orientation is the boundary, since the meeting serves development and regulatory leaders more than commercial or investor audiences.
Best Suited For: Regulatory affairs, clinical development, and medical affairs leaders working on global development and approval strategy.
What to Look for in a Biotech and Life Sciences Conference
Audience Seniority and Composition
The single strongest predictor of value is who is actually in the room. A forum of senior decision-makers working through live commercial and access questions yields more than a large floor where engagement is diluted across thousands of attendees. Examine the published attendee profile, the seniority mix, and the balance between industry, investors, and the customers a team is trying to reach before committing budget or executive time.
Format and Access Structure
Format determines what kind of exchange is possible. Large conventions concentrate interaction into exhibit halls and scheduled partnering meetings, while closed-door forums with capped attendance and enforced ratios are built for candid dialogue. Match the format to the outcome the organization needs, whether that is broad market scanning, structured investor partnering, or deep peer problem-solving with the people who govern adoption.
Topical Relevance in relation to Industry Landscape
The issues commanding attention in life sciences are specific: AI in drug discovery and commercialization, GLP-1 and cardiometabolic strategy, cell and gene therapy access and manufacturing, value-based and outcomes-based contracting, and the implementation of recent drug pricing policy. Read the session-level agenda rather than the event title, which is a weak proxy for whether a program addresses current priorities.
Partnering and Networking Quality
The relationships and deals that persist tend to form where conversation develops on its own terms, not in high-throughput networking designed for maximum contact count. Structured partnering platforms serve a defined business development purpose, and retreat-style settings with curated attendance generally produce fewer introductions of higher quality. Both can be the right trade depending on whether the goal is volume of meetings or depth of relationship.
Continuity and Sustained Relationships
A relationship sustained with the same group across multiple gatherings compounds in a way that single-event attendance cannot. Programs that reconvene the same executives through the year deserve more weight in a recurring budget than one-time gatherings of similar size, because the value accrues over time rather than in a single visit.
Building a Deliberate 2026 and 2027 Biotech and Life Sciences Conference Strategy
A conference calendar should be built around the teams that need to be in the room, and the format choices will follow. Investors and business development leads belong at the capital and partnering events, where the J.P. Morgan Healthcare Conference, the BIO International Convention, Biotech Showcase, and the BIO CEO and Investor Conference concentrate the financing and licensing conversations. Teams scaling cell and gene therapy are served by the science and modality track, anchored by Advanced Therapies Week. Development, quality, and operations leaders find their forums in regulatory and manufacturing events such as the DIA Global Annual Meeting and the ISPE Annual Meeting and Expo. Go-to-market and digital strategy leads belong at the innovation and commercial events, HLTH USA and Fierce Pharma Week. Each format serves a distinct function, so let the calendar follow the work rather than the other way around.
Executive access occupies the tier that the large events cannot fill. The Health Management Academy's Industry Executive Convening, including the Oncology Forum, the Cardiovascular Forum, and the Pharmacy Growth Collaborative, delivers sustained, closed-door dialogue with the health system executives who govern pathways, formularies, and adoption, which is the conversation that partnering floors and investor stages are not built to host. A deliberate calendar pairs at least one of these forums with a selection of the major industry events, so a team gains both the wide market view and the candid customer relationships that carry into commercial and medical strategy. Teams that plan this way will enter each new year with sharper positioning and stronger relationships than a stretch of busy but undirected attendance would produce. For deeper sector planning, see THMA's guides to oncology conferences in 2026 and pharmacy conferences in 2026, and the full calendar at our healthcare conferences.